Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Minimum Legal Sale Age for Tobacco, E-Cigarettes Jumps From 18 to 21 in NYC

November 21, 2013
By Anne Landry
Poll

On November 19, New York City Mayor Michael Bloomberg signed legislation (Tobacco 21 [Intro 250-A]) making New York the first major city to ban the sale of cigarettes, certain tobacco products, and e-cigarettes to anyone under 21 years of age, up from age 18.

Will this law have important health benefits?

On November 19, New York City Mayor Michael Bloomberg signed legislation (Tobacco 21 [Intro 250-A]) making New York the first major city to ban the sale of cigarettes, certain tobacco products, and e-cigarettes to anyone under 21 years of age, up from age 18.  (Under the legislation, an e-cigarette is defined as a battery-operated device that contains nicotine and delivers vapor for inhalation.) The new law will go into effect in May 2014.

Stores will be required to post signage with the new minimum legal sale age (MLSA) for purchase of cigarettes, tobacco products, and e-cigarettes. Penalties for retailers that sell these products  to customers younger than 21 years of age include fines of up to $1,000 for a first offense; $2,000 for a second offense; and, for repeat offenses within a 3-year period, revocation of their Tobacco Retailer’s License. New York City’s Department of Finance or Department of Consumer Affairs may also seal a store for up to 60 days for three violations in 3 years of certain provisions of the new law, including violating the MLSA.

A similar bill raising the MLSA to 21 is now before the Council of the District of Columbia, and statewide legislation is under consideration in New Jersey and Hawaii. In 2005, Needham, Massachusetts became the first city to raise the MLSA to 21 years.

Do you believe federal legislation raising the MLSA for cigarettes/tobacco products to 21 could have a meaningful impact on the nation’s health?

Yes
No
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content
Advertisement

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC

Roman Fabbricatore
October 24th 2025
Article

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Frontline Immunotherapy Improves OS vs BRAF/MEK Inhibitors in BRAF+ NSCLC

Russ Conroy
October 20th 2025
Article

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer.


Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Survival Improves With Perioperative Pembrolizumab in Early-Stage NSCLC

Silas Inman
October 20th 2025
Article

Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Related Content
Advertisement

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC

Roman Fabbricatore
October 24th 2025
Article

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Frontline Immunotherapy Improves OS vs BRAF/MEK Inhibitors in BRAF+ NSCLC

Russ Conroy
October 20th 2025
Article

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer.


Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Survival Improves With Perioperative Pembrolizumab in Early-Stage NSCLC

Silas Inman
October 20th 2025
Article

Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.